Journals / Viral Hepatitis Journal / 2017 / Cilt: 23 - Sayı: 3

Entekavire Bağlı Nadir Bir Yan Etki: Hepatomegali ve Steatoz

A Rare Side Effect of Entecavir: Hepatomegaly and Steatosis

Pages
80–82
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The aim of this clinical report was to point out a rare side-effect of entecavir and to share our treatment approach

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Hepatomegaly and steatosis are rare but potentially fatal side-effects of nucleoside analogues.
📊
Key Findings & Data:Here, we present the case of development of hepatomegaly and steatosis in a 53-year-old male who had been treated with entecavir for five years.
💡
Conclusion & Impact:The aim of this clinical report was to point out a rare side-effect of entecavir and to share our treatment approach
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Hepatomegaly and steatosis are rare but potentially fatal side-effects of nucleoside analogues. Here, we present the case of development of hepatomegaly and steatosis in a 53-year-old male who had been treated with entecavir for five years. There were no symptoms of lactic acidosis. At three months after changing entecavir to tenofovir, the liver size returned to normal and maintained within the normal range during the 3-year follow-up. Therefore, it can be presumed that the hepatomegaly and steatosis were due to entecavir therapy. There are very few reports of hepatomegaly and steatosis caused by nucleoside analogues and the majority of the reported cases were associated with lactic acidosis. To the best of our knowledge, there are no previously reported cases of hepatomegaly and steatosis due to entecavir therapy without evidence of lactic acidosis. The aim of this clinical report was to point out a rare side-effect of entecavir and to share our treatment approach

Özet

Hepatomegali ve steatoz nükleozid analoglarının nadir görülen ancak fatal seyredebilen bir yan etkisidir. Bu olgu sunumunda 5 yıl süre ile entekavir tedavisi almakta olan 53 yaşında erkek hastada hepatomegali ve steatoz gelişimi sunulmuştur. Hastada entekavir tedavisi sırasında laktik asidoz bulgusu olmaksızın progresif hepatomegali ve steatoz gelişmiştir. Entekavir tedavisi tenofovir ile değiştirildikten 3 ay sonra karaciğer boyutu normalleşmiş ve tenofovir tedavisinin ilk 3 yılında normal aralıkta seyretmiştir. Bu nedenle, hepatomegali ve steatozun entekavir tedavisine bağlı gelişmiş olması muhtemeldir. Nükleozid analoglarının neden olduğu hepatomegali ve steatoz nadirdir ve bildirilen olguların çoğunda laktik asidoz ile ilişkilidir. Bildiğimiz kadarıyla daha önce entekavir tedavisine sekonder, laktik asidoz bulgusu olmaksızın gelişen hepatomegali ve steatoz olgusu bildirilmemiştir. Bu olgu sunumunun amacı entekavirin nadir görülen bir yan etkisini ortaya koymak ve uygulanan tedavi yaklaşımını paylaşmaktır

🔖

Cite This Article

BAL, T., ÖNLEN, Y., ŞAHİN, S. İ. (2017). Entekavire Bağlı Nadir Bir Yan Etki: Hepatomegali ve Steatoz. Viral Hepatitis Journal, Cilt: 23 - Sayı: 3, 80–82. https://ajindex.com/articles/332634

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Ridruejo E, Silva MO. Safety of long-term nucleos(t)ide treatment in chronic hepatitis B. Expert Opin Drug Saf. 2012
  2. Fung J, Seto WK, Lai CL, Yuen MF. Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. J Gastroenterol Hepatol. 2014
  3. Entecavir [package insert]. Princeton, NJ: Bristol-Meyers Squibb
  4. Cohen SM, Levy RM, Jovanovich JF, Ahn J. Fatal lactic acidosis associated with the use of combination oral medications to treat reactivation of hepatitis B. J Clin Gastroenterol. 2009
  5. Mao H, Kang T. Lactic Acidosis during Entecavir Antiviral Treatment in a Patient with Hepatitis B Virus-related Decompensated Cirrhosis. West Indian Med J. 2015
  6. Lange CM, Bojunga J, Hoffmann WP, Wunder K, Mihm U, Zeuzem S, Sarrazin C. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology. 2009
  7. Kayaaslan B, Guner R. Adverse effects of oral antiviral therapy in chronic hepatitis B. World J Hepatol. 2017
  8. Morris AA, Carr A. HIV nucleoside analogues: new adverse effects on mitochondria? Lancet. 1999
  9. Patel V, Hedayati SS. Lactic asidosis in an HIV-infected patients receiving highly active antiretroviral therapy. Nat Clin Pract Nephrol. 2006
  10. ter Hofstede HJ, Koopmans PP, van Haelst UJ. Hepatic steatosis during treatment with zidovudine and lamivudine in an HIVpositive patient. Ned Tijdschr Geneeskd. 1998
  11. John M, Mallal S. Hyperlactatemia syndromes in people with HIV infection. Curr Opin Infect Dis. 2002
  12. Delgado J, Harris M, Tesiorowski A, Montaner JS. Symptomatic elevations of lactic acid and their response to treatment manipulation in human immunodeficiency virus-infected persons: a case series. Clin Infect Dis. 2001
  13. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J